malignant wound
Conditions
Interventions
Mohs paste will be applied for 30 minutes, 1 hour, 2 hours, or 4 hours.
Sponsors
Research Hospital, The Institute of Medical Science, The University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who were diagnosed as a solid carcinoma pathologically or clinically. 2)Patients who are suffering from bleeding from malignant wound. 3)Patients who are able to be hospitalized. 4)Patients who had a surgery, a radiation therapy, or a chemotherapy (except hormone therapies) over 2 weeks ago. 5)Patients whose life expectancy is estimated more than 4 weeks. 6)Voluntarily signed the written consent form.
Exclusion criteria
Exclusion criteria: 1)Patients who have uncontrolled or active infection except the target malignant wound. 2)Patients who have allergy to zinc or fradiomycin sulfate. 3)Patients who have applied Mohs paste the same target lesion. 4)Patients who have applied the paste that dose not aim to prevent from protecting surface of malignant wound. 5)Patients who are used anticoagulation drug or antithrombocyte drug. 6)Patients whose malignant wound locates near body cavities or large blood vessels. 7)Patients who may be difficult to keep their safe or to evaluate this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the duration limiting toxicity of Mohs paste application for bleeding from malignant wound | — |
Secondary
| Measure | Time frame |
|---|---|
| the incidence of adverse events the rate of achieving hemostasis the duration of hemostasis the change of QOL of the patients | — |
Countries
Japan
Contacts
Public ContactTsukuru Chiba
Research Hospital, The Institute of Medical Science, The University of Tokyo Department of Palliative Medicine
Outcome results
None listed